Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00566306|
Recruitment Status : Completed
First Posted : December 3, 2007
Last Update Posted : August 26, 2008
|Condition or disease||Intervention/treatment||Phase|
|Clostridium Difficile||Other: Polyhexamethyleneguanidine (PHMG)||Not Applicable|
Environmental disinfection has been proved to be efficient when controlling epidemics caused by C. difficile. In recent years its epidemiology has changed leading to increased morbidity and mortality in many countries. C. difficile infections are often difficult to treat and reinfections frequently occur. The major concern is a new strain of C. difficile, O27, which produce many times more spores than other types and spreads easily in institutions. Patients who have a C. difficile infection should be kept in contact isolation in hospitals and other institutions.
C. difficile is a spore forming bacteria which is resistant to some normally used disinfectants like alcohol and quats. Spores may remain viable for months in environment. Disinfectants currently in use, like chloramines and glutaralde-hyde, are risk both for workers and to environment because of their corrosive and irritating nature.
Polyhexamethyleneguanidine(PHMG) is a new disinfectant which is effective against microbes including bacteria and bacterial spores, viruses and fungi, safe to people handling it and friendly to environment and surfaces. It has been tested in the laboratory of Helsinki University according to many EN-standards to disinfectants. It can be used as a hand disinfectant, instrument disinfectant and surface disinfectant.
PHMG was introduced in three wards for hand hygiene and environmental disinfection in CDAD patients' rooms. The rooms for showers and toilets were coated with biocide coating (PHMG) as well as bed frames in investigational wards. Three wards were control wards and continued using alcohol based hand disinfectants and routine environmental cleaning and disinfection with quats/chloramines. After 6 month's intervention period, the incidence of CDAD cases were compared to that during the preceeding 10 months. Surveillance for environmental and HCWs´ hand contamination by C. difficile were performed by taking microbiological samples both from environmental sites and hands twice before intervention and then twice in month within intervention period.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation|
|Study Start Date :||February 2007|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||August 2008|
PHMG will be introduced in three wards for hand hygiene and environmental disinfection in CDAD patients' rooms. The rooms for showers and toilets will be coated with biocide coating (PHMG) as well as bed frames in investigational wards.
Other: Polyhexamethyleneguanidine (PHMG)
6 months in 3 experimental wards
Other Name: Desisoft
No Intervention: B
Three wards will be control wards and continue using alcohol based hand disinfectants and routine environmental cleaning and disinfection with quats/chloramines.
- Clinical: C. difficile infections on study wards. Microbiologic: C difficile colonization. [ Time Frame: 2/07-5/08 ]
- Economical: to evaluate cost of C difficile infection [ Time Frame: 2/07-5/08 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00566306
|Principal Investigator:||Mari Kanerva, MD,PhD||Helsinki University Central Hospital, Department of Medicine, Division of Infectious Diseases|